1. Home
  2. CRDF vs OACC Comparison

CRDF vs OACC Comparison

Compare CRDF & OACC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRDF
  • OACC
  • Stock Information
  • Founded
  • CRDF 1999
  • OACC 2024
  • Country
  • CRDF United States
  • OACC United States
  • Employees
  • CRDF N/A
  • OACC N/A
  • Industry
  • CRDF Biotechnology: Biological Products (No Diagnostic Substances)
  • OACC
  • Sector
  • CRDF Health Care
  • OACC
  • Exchange
  • CRDF Nasdaq
  • OACC NYSE
  • Market Cap
  • CRDF 288.7M
  • OACC 250.5M
  • IPO Year
  • CRDF N/A
  • OACC 2024
  • Fundamental
  • Price
  • CRDF $3.06
  • OACC $10.16
  • Analyst Decision
  • CRDF Strong Buy
  • OACC
  • Analyst Count
  • CRDF 4
  • OACC 0
  • Target Price
  • CRDF $12.00
  • OACC N/A
  • AVG Volume (30 Days)
  • CRDF 1.1M
  • OACC 67.5K
  • Earning Date
  • CRDF 05-01-2025
  • OACC 01-01-0001
  • Dividend Yield
  • CRDF N/A
  • OACC N/A
  • EPS Growth
  • CRDF N/A
  • OACC N/A
  • EPS
  • CRDF N/A
  • OACC N/A
  • Revenue
  • CRDF $683,000.00
  • OACC N/A
  • Revenue This Year
  • CRDF N/A
  • OACC N/A
  • Revenue Next Year
  • CRDF N/A
  • OACC N/A
  • P/E Ratio
  • CRDF N/A
  • OACC N/A
  • Revenue Growth
  • CRDF 39.96
  • OACC N/A
  • 52 Week Low
  • CRDF $2.01
  • OACC $9.99
  • 52 Week High
  • CRDF $6.38
  • OACC $10.50
  • Technical
  • Relative Strength Index (RSI)
  • CRDF 32.85
  • OACC N/A
  • Support Level
  • CRDF $3.65
  • OACC N/A
  • Resistance Level
  • CRDF $3.88
  • OACC N/A
  • Average True Range (ATR)
  • CRDF 0.21
  • OACC 0.00
  • MACD
  • CRDF -0.08
  • OACC 0.00
  • Stochastic Oscillator
  • CRDF 9.30
  • OACC 0.00

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").

About OACC OAKTREE ACQUISITION CORP III LIFE S

Oaktree Acquisition Corp III Life Sciences is a blank check company.

Share on Social Networks: